Kura Oncology/$KURA
1D1W1MYTD1Y5YMAX
Capital at risk
About Kura Oncology
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
- Ticker
- $KURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 260
- Headquarters
- San Diego, United States
- Website
- kuraoncology.com
Kura Oncology Metrics
BasicAdvanced
$1B
-
-$3.36
0.38
-
Price and volume
Market cap
$1B
Beta
0.38
52-week high
$13.90
52-week low
$7.36
Average daily volume
2.1M
Financial strength
Current ratio
4.733
Quick ratio
4.502
Long term debt to equity
0.391
Total debt to equity
0.505
Interest coverage (TTM)
-224.01%
Profitability
EBITDA (TTM)
-316.799
Gross margin (TTM)
-236.72%
Net profit margin (TTM)
-384.30%
Operating margin (TTM)
-411.90%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-31.30%
Return on equity (TTM)
-167.71%
Valuation
Price to revenue (TTM)
13.217
Price to book
21.23
Price to tangible book (TTM)
21.23
Price to free cash flow (TTM)
-8.692
Free cash flow yield (TTM)
-11.51%
Free cash flow per share (TTM)
-1.33
Growth
Revenue change (TTM)
-7.27%
Earnings per share change (TTM)
48.78%
3-year earnings per share growth (CAGR)
17.92%
10-year earnings per share growth (CAGR)
7.41%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Analyst projections of the future price of Kura Oncology stock.
Bulls say / Bears say
In its second full commercial quarter, KOMZIFTI generated $9.1 million in net product revenue—a 57% sequential increase—while capturing a majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor class ( Reuters ).
As of December 31, 2025, Kura held $667.2 million in cash and equivalents and projected its resources would fund operations into late 2027, reducing near-term dilution risk ( Reuters ).
Preliminary Phase 1a data presented at ASCO 2026 for darlifarnib plus adagrasib showed confirmed objective response rates of 67% in pancreatic cancer and 94% in KRAS inhibitor-naïve patients, underscoring the potential of its next-generation FTI platform ( Reuters ).
Despite accelerating sales, Kura remains deeply unprofitable, reporting a net loss of $68.3 million in Q2 2026—worse than the $66.1 million loss in Q2 2025—reflecting heavy R&D and SG&A spending ( Reuters ).
While Kura maintains a strong cash position, the timing mismatch between runway (expected to fund operations into late 2027) and the pivotal KOMET-017 Phase 3 readout in 2028 creates a binary risk that could necessitate additional financing if trial results are delayed or unfavorable ( Reuters ).
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Upcoming events
No upcoming events
Kura Oncology News
AllArticlesVideos
Funds containing Kura Oncology
AllUSDEURGBP
Fund name | Fund size | $KURA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.09% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.09% |
iShares Healthcare Innovation£DRDR | £1B | 0.09% |
iShares Ageing Population€AGED | €822M | 0.07% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.